Recent advances in understanding and managing cholestasis

F1000Research

Volumn 5, Issue , 2016, Pages

  Trauner, Michael ^b   Wagner, Martin ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER; APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER INHIBITOR; BILE ACID; BILE ACID SEQUESTRANT; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; FEXARAMINE; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 19 MIMETICS; HORMONE RECEPTOR STIMULATING AGENT; MEMBRANE PROTEIN; NORURSODEOXYCHOLIC ACID; OBETICHOLIC ACID; PEPTIDOMIMETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROTEIN INHIBITOR; PX 102; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ANTIINFLAMMATORY ACTIVITY; BILE ACID METABOLISM; BILIARY FIBROSIS; BILIARY TRACT DISEASE; BLOATING; CHOLANGITIS; CHOLELITHIASIS; CHOLESTASIS; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENTEROHEPATIC CIRCULATION; HEADACHE; HUMAN; INTRAHEPATIC CHOLESTASIS; LIVER INJURY; METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY BILIARY CHOLANGITIS; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PRURITUS; REVIEW;

EID: 84978503107     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.8012.1     Document Type: Review

References (76)

1. Hirschfield GM: Genetic determinants of cholestasis. Clin Liver Dis. 2013;17(2):147-59. 23540495 10.1016/j.cld.2012.12.002
2. Monte MJ Marin JJ Antelo A: Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol. 2009;15(7):804-16. 19230041 10.3748/wjg.15.804 2653380
3. Gomez-Ospina N Potter CJ Xiao R: Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun. 2016;7:10713. 26888176 10.1038/ncomms10713 4759630 F1000 Recommendation
4. Vaz FM Paulusma CC Huidekoper H: Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology. 2015;61(1):260-7. 24867799 10.1002/hep.27240 F1000 Recommendation
5. Poupon R Ping C Chrétien Y: Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol. 2008;49(6):1038-45. 18930330 10.1016/j.jhep.2008.07.027 F1000 Recommendation
6. Sambrotta M Strautnieks S Papouli E: Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet. 2014;46(4):326-8. 24614073 10.1038/ng.2918 4061468 F1000 Recommendation
7. Geier A Fickert P Trauner M: Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(10):574-85. 17008927 10.1038/ncpgasthep0602
8. Russell DW: The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137-74. 12543708 10.1146/annurev.biochem.72.121801.161712
9. Wagner M Zollner G Trauner M: New molecular insights into the mechanisms of cholestasis. J Hepatol. 2009;51(3):565-80. 19595470 10.1016/j.jhep.2009.05.012
10. Thomas C Pellicciari R Pruzanski M: Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7(8):678-93. 18670431 10.1038/nrd2619
11. Boyer JL: Bile formation and secretion. Compr Physiol. 2013;3(3):1035-78. 23897680 10.1002/cphy.c120027 4091928
12. Beuers U Maroni L Elferink RO: The biliary HCO(3)(-) umbrella: experimental evidence revisited. Curr Opin Gastroenterol. 2012;28(3):253-7. 22450897 10.1097/MOG.0b013e328352aab2
13. Trauner M Wagner M Fickert P: Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol. 2005;39(4 Suppl 2):S111-24. 15758646 10.1097/01.mcg.0000155551.37266.26
14. Inagaki T Choi M Moschetta A: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2(4):217-25. 16213224 10.1016/j.cmet.2005.09.001 F1000 Recommendation
15. Pandak WM Li YC Chiang JY: Regulation of cholesterol 7 alpha-hydroxylase mRNA and transcriptional activity by taurocholate and cholesterol in the chronic biliary diverted rat. J Biol Chem. 1991;266(6):3416-21. 1995604
16. Matsubara T Li F Gonzalez FJ: FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2013;368(1-2):17-29. 22609541 10.1016/j.mce.2012.05.004 3491147
17. Lefebvre P Cariou B Lien F: Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147-91. 19126757 10.1152/physrev.00010.2008
18. Wang L Lee YK Bundman D: Redundant pathways for negative feedback regulation of bile acid production. Dev Cell. 2002;2(6):721-31. 12062085 10.1016/S1534-5807(02)00187-9
19. Bookout AL Jeong Y Downes M: Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 2006;126(4):789-99. 16923397 10.1016/j.cell.2006.06.049 F1000 Recommendation
20. Moschetta A Bookout AL Mangelsdorf DJ: Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004;10(12):1352-8. 15558057 10.1038/nm1138 F1000 Recommendation
21. Wang YD Chen WD Wang M: Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48(5):1632-43. 18972444 10.1002/hep.22519 3056574 F1000 Recommendation
22. Wagner M Zollner G Trauner M: Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation. Hepatology. 2008;48(5):1383-6. 18972560 10.1002/hep.22668
23. Zhang H Liu Y Bian Z: The critical role of myeloid-derived suppressor cells and FXR activation in immune-mediated liver injury. J Autoimmun. 2014;53:55-66. 24721598 10.1016/j.jaut.2014.02.010
24. Beuers U Trauner M Jansen P: New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015;62(1 Suppl):S25-37. 25920087 10.1016/j.jhep.2015.02.023
25. Lindor KD Gershwin ME Poupon R: Primary biliary cirrhosis. Hepatology. 2009;50(1):291-308. 19554543 10.1002/hep.22906
26. Poropat G Giljaca V Stimac D: Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2011; (1):CD003626. 21249655 10.1002/14651858.CD003626.pub2
27. Yoon YB Hagey LR Hofmann AF: Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology. 1986;90(4):837-52. 3949115
28. Fickert P Wagner M Marschall HU: 24- norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2006;130(2):465-81. 16472600 10.1053/j.gastro.2005.10.018
29. Halilbasic E Fiorotto R Fickert P: Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2 -/- mice. Hepatology. 2009;49(6):1972-81. 19475687 10.1002/hep.22891 3569724
30. Moustafa T Fickert P Magnes C: Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology. 2012;142(1):140-151.e12. 22001865 10.1053/j.gastro.2011.09.051
31. Fickert P Pollheimer MJ Silbert D: Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol. 2013;58(6):1201-8. 23369794 10.1016/j.jhep.2013.01.026 3650580
32. Trauner M Halilbasic E Claudel T: Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. Dig Dis. 2015;33(3):433-9. 26045280 10.1159/000371904
33. Pellicciari R Fiorucci S Camaioni E: 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45(17):3569-72. 12166927 10.1021/jm025529g F1000 Recommendation
34. Fiorucci S Clerici C Antonelli E: Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther. 2005;313(2):604-12. 15644430 10.1124/jpet.104.079665 F1000 Recommendation
35. 3 output. Hepatology. 2011;54(4):1303-12. 22006858 10.1002/hep.24537 3744065
36. Liu Y Binz J Numerick MJ: Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003;112(11):1678-87. 14623915 10.1172/JCI18945 281645 F1000 Recommendation
37. Modica S Petruzzelli M Bellafante E: Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology. 2012;142(2):355-65.e1-4. 22057115 10.1053/j.gastro.2011.10.028 F1000 Recommendation
38. Fang S Suh JM Reilly SM: Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015;21(2):159-65. 25559344 10.1038/nm.3760 4320010 F1000 Recommendation
39. Hirschfield GM Mason A Luketic V: Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(4):751-61.e8. 25500425 10.1053/j.gastro.2014.12.005
40. Neuschwander-Tetri BA Loomba R Sanyal AJ: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956-65. 25468160 10.1016/S0140-6736(14)61933-4 4447192 F1000 Recommendation
41. Neuschwander-Tetri BA: Targeting the FXR nuclear receptor to treat liver disease. Gastroenterology. 2015;148(4):704-6. 25724453 10.1053/j.gastro.2015.02.037
42. Nevens F Andreone P Mazzella G: O168 the first primary biliary cirrhosis (PBC) phase 3 trial in two decades - an international study of the FXR agonist obeticholic acid in PBC patients. J Hepatol. 2014;60(1):S525-S526. 10.1016/S0168-8278(14)61463-X
43. Trauner M Nevens F Andreone P: Sustained improvement in the markers of cholestasis in an open label long term safety extension study of obeticholic acid in primary biliary cirrhosis patients. Hepatology. 2015;62:511A (Abstract). Reference Source
44. Wunsch E Milkiewicz M Wasik U: Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. Sci Rep. 2015;5: 13462. 26293907 10.1038/srep13462 4544021 F1000 Recommendation
45. Zweers SJ Booij KA Komuta M: The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology. 2012;55(2):575-83. 21953282 10.1002/hep.24702 F1000 Recommendation
46. Luo J Ko B Elliott M: A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med. 2014;6(247):247ra100. 25080475 10.1126/scitranslmed.3009098 F1000 Recommendation
47. Nicholes K Guillet S Tomlinson E: A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol. 2002;160(6):2295-307. 12057932 10.1016/S0002-9440(10)61177-7 1850847
48. Sawey ET Chanrion M Cai C: Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell. 2011;19(3):347-58. 21397858 10.1016/j.ccr.2011.01.040 3061399
49. Zhou M Learned RM Rossi SJ: Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology. 2016;63(3):914-29. 26418580 10.1002/hep.28257 F1000 Recommendation
50. Mayo MJ Roberts SK Arnold H: NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial. Hepatology. 2015;62(Suppl. 1):263A (Abstract). Reference Source
51. Kir S Beddow SA Samuel VT: FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331(6024):1621-4. 21436455 10.1126/science.1198363 3076083 F1000 Recommendation
52. Walters JR Tasleem AM Omer OS: A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol. 2009;7(11):1189-94. 19426836 10.1016/j.cgh.2009.04.024 F1000 Recommendation
53. Walters JR: Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2014;11(7):426-34. 24662279 10.1038/nrgastro.2014.32
54. Owen BM Mangelsdorf DJ Kliewer SA: Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab. 2015;26(1):22-9. 25476453 10.1016/j.tem.2014.10.002 4277911
55. Rysz J Gluba-Brzózka A Mikhailidis DP: Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. Expert Opin Investig Drugs. 2015;24(5):603-10. 25604607 10.1517/13543784.2015.1006357
56. Dawson PA Haywood J Craddock AL: Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem. 2003;278(36):33920-7. 12819193 10.1074/jbc.M306370200 F1000 Recommendation
57. Lundåsen T Andersson EM Snaith M: Inhibition of intestinal bile acid transporter Slc10a2 improves triglyceride metabolism and normalizes elevated plasma glucose levels in mice. PLoS One. 2012;7(5):e37787. 22662222 10.1371/journal.pone.0037787 3360597 F1000 Recommendation
58. Trivedi PJ Ward S: Altered bile acid pool using IBAT inhibitors for constipation: a potentially increased risk of malignancy. Am J Gastroenterol. 2012;107(1):140; author reply 140-1. 22218036 10.1038/ajg.2011.378
59. Raufman JP Dawson PA Rao A: Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. Carcinogenesis. 2015;36(10):1193-200. 26210740 10.1093/carcin/bgv107 4612337 F1000 Recommendation
60. Miethke AG Zhang W Simmons J: Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology. 2016;63(2):512-23. 26172874 10.1002/hep.27973 4713368 F1000 Recommendation
61. Baghdasaryan A Fuchs CD Österreicher CH: Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol. 2016;64(3):674-81. 26529078 10.1016/j.jhep.2015.10.024
62. Marschall HU Gillberg P Graffner H: The ileal bile acid transporter inhibitor A4250 modulates bile acid synthesis and decreases serum bile acids. Hepatology. 2015;62:612A (Abstract).
63. Jacobson TA Armani A McKenney JM: Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol. 2007;99(6A):47C-55C. 17368279 10.1016/j.amjcard.2006.11.022
64. Harach T Pols TW Nomura M: TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep. 2012;2:430. 22666533 10.1038/srep00430 3362799
65. Inagaki T Moschetta A Lee Y: Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103(10):3920-5. 16473946 10.1073/pnas.0509592103 1450165 F1000 Recommendation
66. Fouts DE Torralba M Nelson KE: Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol. 2012;56(6):1283-92. 22326468 10.1016/j.jhep.2012.01.019 3357486
67. Honda A Ikegami T Nakamuta M: Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57(5):1931-41. 22911624 10.1002/hep.26018 F1000 Recommendation
68. Kok T Bloks VW Wolters H: Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J. 2003;369(Pt 3):539-47. 12381268 10.1042/BJ20020981 1223107 F1000 Recommendation
69. 4. J Lipid Res. 2004;45(10):1813-25. 15258199 10.1194/jlr.M400132-JLR200
70. Wagner M Zollner G Trauner M: Nuclear receptors in liver disease. Hepatology. 2011;53(3):1023-34. 21319202 10.1002/hep.24148
71. Arenas F Hervias I Uriz M: Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest. 2008;118(2):695-709. 18188457 2176189 F1000 Recommendation
72. Gonzales E Grosse B Schuller B: Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology. 2015;62(2):558-66. 25716872 10.1002/hep.27767 F1000 Recommendation
73. Gonzales E Grosse B Cassio D: Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. J Hepatol. 2012;57(3):695-8. 22609309 10.1016/j.jhep.2012.04.017 F1000 Recommendation
74. 4. J Biol Chem. 2012;287(7):5070-8. 22184139 10.1074/jbc.M111.275438 3281624
75. van der Velden LM Lieke JM Stapelbroek JM: Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate. Hepatology. 2010;51(1):286-96. 19918981 10.1002/hep.23268
76. van der Woerd WL Kokke FT van der Zee DC: Total biliary diversion as a treatment option for patients with progressive familial intrahepatic cholestasis and Alagille syndrome. J Pediatr Surg. 2015;50(11):1846-9. 26319776 10.1016/j.jpedsurg.2015.07.016